Navigation Links
Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Date:8/1/2008

SAN DIEGO, Aug. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Bank of America 2008 Specialty Pharmaceuticals Conference on Friday, August 8, 2008 at 8:45 a.m. EDT (5:45 a.m. PDT). The conference is being held at the Southampton Inn in Long Island, New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through August 22, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing ANA598, a non-nucleoside polymerase inhibitor, and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develo
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
2. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
3. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
5. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
6. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
7. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
8. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
11. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2013)... 11, 2013 It is with deepest ... MD. Dr. Dulaney, one of the founding partners of ... changing people’s lives through advanced vision care . ... innovative technology solutions and the potential of individuals. While ... he retired from the practicing in 2006, many patients, ...
(Date:12/10/2013)... December 10, 2013 Tanja Dominko, ... at Worcester Polytechnic Institute (WPI), is the 2013 ... to one Slovenian native each year in recognition ... award also honors Dominko's international engagement in developing ... members with Slovenian colleagues to address important biomedical ...
(Date:12/10/2013)... 2013 According to ... Applications in Risk Assessment, Molecular Diagnostics, Disease ... Forensic Applications and Others) - Global Industry ... Size, Share, Opportunities and Forecast, 2013 - ... global biomarkers market for diagnostic applications such ...
(Date:12/10/2013)... FRANCISCO, Calif. , Dec. 10, 2013 /PRNewswire/ ... development of novel cancer therapeutics, today announced the ... therapeutic candidate, CB-839, at the 55 th ... is a potent, selective, orally available glutaminase inhibitor ... cell growth and survival.  "Glutaminase ...
Breaking Biology Technology:Barnet Dulaney Perkins Eye Center Regrets to Announce the Passing of David Dulaney, MD 2Worcester Polytechnic Institute’s Tanja Dominko Named Slovenian Ambassador of Science for 2013 2Worcester Polytechnic Institute’s Tanja Dominko Named Slovenian Ambassador of Science for 2013 3Worcester Polytechnic Institute’s Tanja Dominko Named Slovenian Ambassador of Science for 2013 4Biomarker Market for Diagnostic Applications is Expected to Reach $30.6 Billion Globally by 2020 - Allied Market Research 2Biomarker Market for Diagnostic Applications is Expected to Reach $30.6 Billion Globally by 2020 - Allied Market Research 3Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting 2
... consolidated revenues rise 3% over Fiscal 2006 to $27.5 ... are in Canadian dollars unless otherwise noted), BELLEVILLE, ... BNC), a research-based, technology-driven Canadian,biopharmaceutical company, today announced financial ... "The recent announcements of the first shipment and ...
... the Asia-Pacific ... ... PAREXEL International,Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical ... APEX International Clinical Research Co., Ltd. ("APEX").,The acquisition strengthens PAREXEL,s ...
... (Nasdaq: NSTK ) will be hosting an analyst ... October 4, 2007,from 12:00 p.m. - 3:00 p.m. Eastern ... 270 West 43rd Street. The luncheon event will feature ... and,Chief Executive Officer and Gordon Brandt, M.D., Executive Vice ...
Cached Biology Technology:Bioniche Reports Fiscal 2007 Year-End Results 2Bioniche Reports Fiscal 2007 Year-End Results 3Bioniche Reports Fiscal 2007 Year-End Results 4Bioniche Reports Fiscal 2007 Year-End Results 5Bioniche Reports Fiscal 2007 Year-End Results 6Bioniche Reports Fiscal 2007 Year-End Results 7Bioniche Reports Fiscal 2007 Year-End Results 8Bioniche Reports Fiscal 2007 Year-End Results 9Bioniche Reports Fiscal 2007 Year-End Results 10PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd. 2PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd. 3PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd. 4PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd. 5Nastech to Host 2007 Analyst and Institutional Investor Day 2Nastech to Host 2007 Analyst and Institutional Investor Day 3
(Date:12/11/2013)... that results from the death of certain neurons in the ... movements. , The neurodegenerative disease is caused by a defect ... in a part of DNA, called a CAG codon or ... version of the Htt gene has between 20 and 23 ... long repeats of the CAG triplet, resulting in the mutant ...
(Date:12/11/2013)... at the UNC School of Medicine and the Medical ... gene therapy led to a dramatic decline in bleeding ... serious and costly bleeding condition that affects about 50,000 ... the world. , Before the gene treatment, the animals ... receiving the novel gene therapy, though, they experienced substantially ...
(Date:12/11/2013)... release is available in German . ... a classical biological laboratory device, but it is no ... lose validity, as cell behavior on a flat plastic ... example. Researchers of Karlsruhe Institute of Technology have now ... repellent for certain types of cells (DOI: 10.1002/adma.201302492 and ...
Breaking Biology News(10 mins):Staying ahead of Huntington's disease 2New gene therapy proves promising as hemophilia treatment 2New gene therapy proves promising as hemophilia treatment 3Precise docking sites for cells 2
... from the Arctic to the Antarctic has successfully produced ... the atmosphere, scientists announced today. The far-reaching field ... the first detailed mapping of the global distribution of ... series of flights, which come to an end next ...
... A new commercial processing technology is suitable for boosting ... effects on other nutrients in those tasty delicacies, the first ... exposing mushrooms to the same kind of ultraviolet light that ... appears in ACS, Journal of Agricultural and Food Chemistry ...
... thousands of proteins whose activity and lifetime must be regulated to ... The heat shock protein Hsp90 plays a key role in this ... were. It monitors and controls the quality and activity of many ... When the cell is exposed to high stress levels from heat ...
Cached Biology News:First global portrait of greenhouse gases emerges from pole-to-pole flights 2First global portrait of greenhouse gases emerges from pole-to-pole flights 3First global portrait of greenhouse gases emerges from pole-to-pole flights 4A chaperone for the 'guardian of the genome' 2A chaperone for the 'guardian of the genome' 3
... White solid.. PACKAGED UNDER INERT GAS. Cyclizes ... is "driven" to completion. A protective agent for ... in many other preparations. Blocks the lethal and ... titration. Contaminants: Heavy metals: ≤1 ppm. ...
... Faster speeds, highest precision, more user-friendliness and ... this is the definition of the Mastercycler ... nucleic acid research has been developing dynamically. ... of PCR Systems. To keep pace ...
... The recent sequencing of Salmonella genomes ... enterica Typhimurium ORFmer PCR* primer pairs. The ... of a single chromosome (4,857,432 bp; 4,440 ... 107 ORFs). These ORFmers from Sigma-Genosys have ...
... This kit is designed for easy transformation ... protocol allows for successful transformation simply by ... reagents with cultured yeast cells. No complicated ... are required. The kit is particularly well ...
Biology Products: